Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
Exposure to Particulate Matter on the London Underground in Healthy Subjects and Patients With Chronic Respiratory Disease
NCT number | NCT04614064 |
Other study ID # | 20SM6236 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | August 16, 2021 |
Est. completion date | July 20, 2023 |
Verified date | July 2023 |
Source | Imperial College London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
An average of 4.8 million journeys are made on the London Underground every day and as the 'Tube' has elevated airborne particulate matter concentrations compared to ambient air, this raises concern about the potential health impact of this environment. This study explores the health effects of particulate matter from the London Underground on patients with COPD and healthy volunteers. Patients with COPD and healthy participants will be invited to undertake a set 90 min journey on the London Underground, and on a separate occasion (3-8 weeks apart), a 90 min journey on the London Overground (as a proxy for a clean air London area while maintaining other aspects of a train journey). A series of clinical, physiological and inflammatory data will be collected before, during and after (at different time points) each of the sessions in order to compare their response in relation to exposure and/or to disease status.
Status | Completed |
Enrollment | 83 |
Est. completion date | July 20, 2023 |
Est. primary completion date | July 20, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years to 90 Years |
Eligibility | Inclusion Criteria for both groups: - Give informed consent - London resident For participants with COPD: - GOLD stage 2 COPD (FEV1/FVC<70%; 50%>FEV1<80% predicted), GOLD stage 3 COPD (FEV1/FVC<70%; 30%>FEV1<50%) and GOLD stage 4 (FEV1/FVC<70%;FEV1<30%) - No history of ischaemic heart disease For healthy volunteers: - No history of ischaemic heart disease. - Normal lung function with no evidence of airflow obstruction. Exclusion Criteria for both participants with COPD and healthy volunteers: - Those with unstable ischaemic heart disease or COPD. - Current smokers and those who are ex-smokers of <12 months duration. - Those who work in the London Underground or are occupationally exposed to - - high levels of vehicle traffic exposure on a frequent basis. - Those who cannot walk for 30 mins. - Involvement in another research study - Those unable to give consent. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Imperial Clinical Research Facility | London |
Lead Sponsor | Collaborator |
---|---|
Imperial College London | Medical Research Council |
United Kingdom,
Sinharay R, Gong J, Barratt B, Ohman-Strickland P, Ernst S, Kelly FJ, Zhang JJ, Collins P, Cullinan P, Chung KF. Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, crossover study. Lancet. 2018 Jan 27;391(10118):339-349. doi: 10.1016/S0140-6736(17)32643-0. Epub 2017 Dec 5. Erratum In: Lancet. 2018 Jan 27;391(10118):308. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The difference (London Underground vs control exposure) in post exposure pulse wave velocity in healthy vs COPD participants. | Measurement of arterial stiffness | -2 hours, +2 hours, +5 hours, +6 hours, +24 hours | |
Secondary | Other clinical responses on the London Underground vs control exposure | Symptom questionnaire | -2 hours, 0 hours, +45 minutes +90 minutes, +4 hours, +5 hours, +6 hours, +24 hours | |
Secondary | Other clinical responses on the London Underground vs control exposure | Spirometry (FEV1) | -2 hours, 0 hours, +45 minutes, +90 minutes, +2 hours, +4 hours, +6 hours, +24 hours | |
Secondary | Other clinical responses on the London Underground vs control exposure | Spirometry (FVC) | -2 hours, 0 hours, +45 minutes, +90 minutes, +2 hours, +4 hours, +6 hours, +24 hours | |
Secondary | Other clinical responses on the London Underground vs control exposure | Spirometry (FEF 25-75) | -2 hours, 0 hours, +45 minutes, +90 minutes, +2 hours, +4 hours, +6 hours, +24 hours | |
Secondary | Other clinical responses on the London Underground vs control exposure | Single breath transfer factor for carbon monoxide (TLCO) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Blood sample (IL8) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Blood sample (High sensitivity CRP) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Blood sample (FBC) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Blood sample (TNFa) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Blood sample (vWf antigen) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Blood sample (Thrombin generation (systemic inflammatory response)) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Blood sample (8-isoprostanes (ELISA)) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Blood sample (Blood malondialdehyde (lipid peroxidation)) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Blood sample (Oxidation Reduction Potential (oxidative stress)) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Nasosorption (IL-8) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Nasosorption (IL-6) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Nasosorption (IL-33) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Nasosorption (Myeloperoxidase) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Nasosorption (Neutrophil lipocalin-2) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Nasosorption (Tryptases) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Nasosorption (Complement) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Nasosorption (vWf antigen) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Nasosorption (Thrombin generation) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Nasosorption (D-dimer activation) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Nasal curettage (mRNA levels to elucidate molecular mechanisms that may explain the toxic effects of particulate matter) | -2 hours, +7 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Urine (8-isoprostane) | -2 hours, +24 hours | |
Secondary | Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure | Urine (8-hydroxy 2-deoxyguanosine) | -2 hours, +24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|